title: Health economics. Perfect combination.
abstract: The assumption by some HAs that a shift from mono to combination drug therapies for HIV results in a proportional increase in drug expenditure, regardless of health gains, is misguided. Methods of calculating anti-HIV drug expenditure have failed to keep up with changing treatment regimes. There is an urgent need to change the way data on antiretroviral use is collected and presented to establish the true cost-effectiveness of new drug regimes.
authors.affiliation: Royal Free Hampstead Trust.
authors.forename: M
authors.initials: M
authors.lastname: Youle
authors.forename: R
authors.initials: R
authors.lastname: Weston
authors.forename: P
authors.initials: P
authors.lastname: Trueman
authors.forename: L
authors.initials: L
authors.lastname: Swaden
authors.forename: H
authors.initials: H
authors.lastname: Leake
mesh_terms: D019380:Anti-HIV Agents / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003625:Data Collection; D016527:Drug Costs; D004359:Drug Therapy, Combination; D005569:Formularies as Topic; D015658:HIV Infections / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D013222:State Medicine / Q000191:economics; D006113:United Kingdom
chemical_list: D019380:Anti-HIV Agents